Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Shire

National Institute for Health and Care Excellence NICE logo

NICE knocks-back Shire’s pancreatic cancer drug Onivyde

Final guidance rules it's not a cost-effective use of NHS resources

Takeda pilots Apple Watch depression app

Partners with Cognition Kit on patient monitoring wearable

- PMLiVE

J&J gets CHMP backing for broader Darzalex use

Recommendation for earlier-stage approval could see multiple myeloma drug reach blockbuster sales

- PMLiVE

TiGenix cell therapy for Crohn’s fistulas shows long-term benefit

Phase III data for the Takeda-partnered drug raises hopes for upcoming EU approval

- PMLiVE

Takeda UK & Ireland appoints market access director

Peter Wheatley Price brings experience from GSK, Janssen and Boehringer Ingelheim

- PMLiVE

A rare talent

Shire’s Sebastian Stachowiak on dealing with change and working for a fit-for-purpose orphan drug environment

Shire Basingstoke

Shire pays record $350m to settle US kickback allegations

Charges centred around diabetic foot ulcer treatment Dermagraft, which it sold in 2014

- PMLiVE

Takeda agrees $5.2bn deal to buy Ariad

Acquires cancer firm in the first big pharma M&A deal of 2017

- PMLiVE

Valeant’s proposed sale of Salix to Takeda ‘in jeopardy’

Canadian firm now intends to grow Salix salesforce to build Xifaxan and Relistor brands

dengue fever mosquito

Takeda plans German plant to support dengue vaccine roll-out

Will invest more than €100m in the Singen manufacturing facility

- PMLiVE

Takeda gets EU green light for oral myeloma drug

Ninlaro first oral proteasome inhibitor to be registered in Europe

- PMLiVE

Shire to focus rare disease R&D with new US facility

Cambridge, Massachusetts hub to drive firm’s push to become leading rare disease specialist

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links